BMS-986406 + nivolumab + carboplatin + paclitaxel

BMS-986406 + nivolumab + carboplatin + paclitaxel is a combination regimen being investigated for advanced solid tumors, including non-small cell lung cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, and others. - **BMS-986406** is a monoclonal antibody that targets LILRB2 (also known as ILT4), reducing immunosuppressive signaling in the tumor microenvironment and aiming to enhance antitumor immune responses[1][6]. - **Nivolumab** is a monoclonal antibody (brand name Opdivo) targeting PD-1 (PDCD1), which increases T-cell activation and anti-tumor immune response[6]. - **Carboplatin** is a small molecule platinum-based chemotherapeutic agent that causes DNA crosslinking and induces apoptosis in cancer cells. - **Paclitaxel** is a small molecule chemotherapeutic agent (taxane) that stabilizes microtubules, preventing cell division, and triggers apoptosis. This combination is used in a Phase I trial for participants with advanced and metastatic solid tumors including non-small cell lung cancer, pancreatic ductal adenocarcinoma, among others[2][5][6].

Other names

BMS986406BMS-986406BMS 986406LILRB2 Antibody 12LILRB-2 Antibody 12LILRB 2 Antibody 12PD-L1/PD-1 antibodypaclitaxelcarboplatin